Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence:: a PEARRL review

Ioannis Loisios-Konstantinidis, Rafael L.M. Paraiso, Nikoletta Fotaki, Mark McAllister, Rodrigo Cristofoletti, Jennifer Dressman

Research output: Contribution to journalReview article

Abstract

Objectives
The objective of this review was to provide an overview of pharmacokinetic/pharmacodynamic (PK/PD) models, focusing on drug‐specific PK/PD models and highlighting their value added in drug development and regulatory decision‐making.

Key findings
Many PK/PD models, with varying degrees of complexity and physiological understanding have been developed to evaluate the safety and efficacy of drug products. In special populations (e.g. paediatrics), in cases where there is genetic polymorphism and in other instances where therapeutic outcomes are not well described solely by PK metrics, the implementation of PK/PD models is crucial to assure the desired clinical outcome. Since dissociation between the pharmacokinetic and pharmacodynamic profiles is often observed, it is proposed that physiologically based pharmacokinetic and PK/PD models be given more weight by regulatory authorities when assessing the therapeutic equivalence of drug products.

Summary
Modelling and simulation approaches already play an important role in drug development. While slowly moving away from ‘one‐size fits all’ PK methodologies to assess therapeutic outcomes, further work is required to increase confidence in PK/PD models in translatability and prediction of various clinical scenarios to encourage more widespread implementation in regulatory decision‐making.
LanguageEnglish
Pages699-723
Number of pages25
JournalJournal of Pharmacy and Pharmacology
Volume71
Issue number4
Early online date22 Feb 2019
DOIs
StatusPublished - 1 Apr 2019

Keywords

  • drug development
  • modelling and simulation
  • pharmacokinetics/pharmacodynamics
  • regulatory science
  • therapeutic equivalence

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. / Loisios-Konstantinidis, Ioannis; Paraiso, Rafael L.M.; Fotaki, Nikoletta; McAllister, Mark; Cristofoletti, Rodrigo; Dressman, Jennifer.

In: Journal of Pharmacy and Pharmacology, Vol. 71, No. 4, 01.04.2019, p. 699-723.

Research output: Contribution to journalReview article

Loisios-Konstantinidis, Ioannis ; Paraiso, Rafael L.M. ; Fotaki, Nikoletta ; McAllister, Mark ; Cristofoletti, Rodrigo ; Dressman, Jennifer. / Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. In: Journal of Pharmacy and Pharmacology. 2019 ; Vol. 71, No. 4. pp. 699-723.
@article{362475ba85e840b5bda09d1722c57a3c,
title = "Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence:: a PEARRL review",
abstract = "ObjectivesThe objective of this review was to provide an overview of pharmacokinetic/pharmacodynamic (PK/PD) models, focusing on drug‐specific PK/PD models and highlighting their value added in drug development and regulatory decision‐making.Key findingsMany PK/PD models, with varying degrees of complexity and physiological understanding have been developed to evaluate the safety and efficacy of drug products. In special populations (e.g. paediatrics), in cases where there is genetic polymorphism and in other instances where therapeutic outcomes are not well described solely by PK metrics, the implementation of PK/PD models is crucial to assure the desired clinical outcome. Since dissociation between the pharmacokinetic and pharmacodynamic profiles is often observed, it is proposed that physiologically based pharmacokinetic and PK/PD models be given more weight by regulatory authorities when assessing the therapeutic equivalence of drug products.SummaryModelling and simulation approaches already play an important role in drug development. While slowly moving away from ‘one‐size fits all’ PK methodologies to assess therapeutic outcomes, further work is required to increase confidence in PK/PD models in translatability and prediction of various clinical scenarios to encourage more widespread implementation in regulatory decision‐making.",
keywords = "drug development, modelling and simulation, pharmacokinetics/pharmacodynamics, regulatory science, therapeutic equivalence",
author = "Ioannis Loisios-Konstantinidis and Paraiso, {Rafael L.M.} and Nikoletta Fotaki and Mark McAllister and Rodrigo Cristofoletti and Jennifer Dressman",
note = "{\circledC} 2019 Royal Pharmaceutical Society.",
year = "2019",
month = "4",
day = "1",
doi = "10.1111/jphp.13070",
language = "English",
volume = "71",
pages = "699--723",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "4",

}

TY - JOUR

T1 - Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence:

T2 - Journal of Pharmacy and Pharmacology

AU - Loisios-Konstantinidis, Ioannis

AU - Paraiso, Rafael L.M.

AU - Fotaki, Nikoletta

AU - McAllister, Mark

AU - Cristofoletti, Rodrigo

AU - Dressman, Jennifer

N1 - © 2019 Royal Pharmaceutical Society.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - ObjectivesThe objective of this review was to provide an overview of pharmacokinetic/pharmacodynamic (PK/PD) models, focusing on drug‐specific PK/PD models and highlighting their value added in drug development and regulatory decision‐making.Key findingsMany PK/PD models, with varying degrees of complexity and physiological understanding have been developed to evaluate the safety and efficacy of drug products. In special populations (e.g. paediatrics), in cases where there is genetic polymorphism and in other instances where therapeutic outcomes are not well described solely by PK metrics, the implementation of PK/PD models is crucial to assure the desired clinical outcome. Since dissociation between the pharmacokinetic and pharmacodynamic profiles is often observed, it is proposed that physiologically based pharmacokinetic and PK/PD models be given more weight by regulatory authorities when assessing the therapeutic equivalence of drug products.SummaryModelling and simulation approaches already play an important role in drug development. While slowly moving away from ‘one‐size fits all’ PK methodologies to assess therapeutic outcomes, further work is required to increase confidence in PK/PD models in translatability and prediction of various clinical scenarios to encourage more widespread implementation in regulatory decision‐making.

AB - ObjectivesThe objective of this review was to provide an overview of pharmacokinetic/pharmacodynamic (PK/PD) models, focusing on drug‐specific PK/PD models and highlighting their value added in drug development and regulatory decision‐making.Key findingsMany PK/PD models, with varying degrees of complexity and physiological understanding have been developed to evaluate the safety and efficacy of drug products. In special populations (e.g. paediatrics), in cases where there is genetic polymorphism and in other instances where therapeutic outcomes are not well described solely by PK metrics, the implementation of PK/PD models is crucial to assure the desired clinical outcome. Since dissociation between the pharmacokinetic and pharmacodynamic profiles is often observed, it is proposed that physiologically based pharmacokinetic and PK/PD models be given more weight by regulatory authorities when assessing the therapeutic equivalence of drug products.SummaryModelling and simulation approaches already play an important role in drug development. While slowly moving away from ‘one‐size fits all’ PK methodologies to assess therapeutic outcomes, further work is required to increase confidence in PK/PD models in translatability and prediction of various clinical scenarios to encourage more widespread implementation in regulatory decision‐making.

KW - drug development

KW - modelling and simulation

KW - pharmacokinetics/pharmacodynamics

KW - regulatory science

KW - therapeutic equivalence

UR - http://www.scopus.com/inward/record.url?scp=85062278358&partnerID=8YFLogxK

U2 - 10.1111/jphp.13070

DO - 10.1111/jphp.13070

M3 - Review article

VL - 71

SP - 699

EP - 723

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 4

ER -